Join us for a webinar where leading experts will discuss the critical role fibroblasts play in metabolic disorders. The presentations will highlight recent research findings and explore the therapeutic potential of modulating fibroblast activity to improve patient outcomes.
We will explore key aspects of fibroblast activity in metabolic health, starting with the metabolic activation and deactivation of fibroblasts in MAFLD (Metabolic Associated Fatty Liver Disease). It highlights the weight-dependent factors influencing these processes and the impact of weight loss on fibroblast behavior in MAFLD.
The discussion then moves to the metabolic activation of extracellular matrix (ECM) production by fibroblasts and its effects on heart, liver, and kidney diseases. Finally, it addresses the potential benefits of pharmacological interventions in modulating fibroblast activation, offering therapeutic possibilities for patients with these conditions.
0:00 Intro
3:46 Metabolic activation of ECM production of fibroblast and the relation to outcomes in heart, liver and kidney diseases – Dr. Morten Karsdal
28:07 Metabolic activation and de-activation of fibroblasts in MAFLD by weight loss. The weight-dependent angle – Dr. Jörn M. Schattenberg
56:00 Pharmacological modulation of fibroblast activation and the benefit for patients –Dr. Diana J. Leeming
1:17:28 General questions
#obesity #cardiovasculardisease #liverdisease #cardiology #drugdevelopment #webinar